ArticleFrontiers in immunology2025
Platelet transfusion refractoriness within one month post-hematopoietic stem cell transplantation does not impair survival in aplastic anemia patients after engraftment: a propensity score-matched analysis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The incidence of platelet transfusion refractoriness (PTR) and its impact on survival outcomes in patients with severe aplastic anemia (SAA) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains unclear. Methods: We investigated the incidence of early PTR (within one month post-allo-HSCT) and its clinical implications in 215 aplastic anemia (AA) patients in a retrospective study. Results: Among the enrolled patients, 24 (11.7%) developed PTR within the first month post-transplantation. Propensity score matching (PSM) was performed, resulting in 24 PTR cases and 96 matched non-PTR controls, with balanced baseline characteristics. No significant differences were observed between the two groups in bloodstream infections, grade II-IV or III-IV acute graft-versus-host disease (aGVHD), viral infections, or engraftment rates. However, PTR patients required significantly more red blood cell (median: 13.5 units vs. 8 units, Conclusion: Our findings suggest that early PTR occurs at a relatively low frequency (11.7%) in AA patients post-allo-HSCT and may not significantly compromise survival outcomes following successful engraftment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.